There is little that resembles a current and all-encompassing drug policy in the United States. A national drug control plan issued by the Obama administration last year was written immediately prior to a White House transition, and many hoping for a newer framework are waiting for next month’s reveal of a new presidential commission’s final report on the opioid epidemic.  

A new analysis by the Kaiser Family Foundation, however, shows that many of the elements that could soon be codified as federal guidance are already creeping toward national standards in a patchwork fashion, apparent in the regulations imposed by a number of states for implementing Medicaid.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy